ELVN Stock Summary and Trading Ideas (Enliven Therapeutics | NASDAQ:ELVN)

Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. The product candidates of the company include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.

Enliven Therapeutics trades on the NASDAQ stock market under the symbol ELVN.

As of September 11, 2026, ELVN stock price declined to $54.32 with 736,111 million shares trading.

ELVN has a beta of 0.92, meaning it tends to be less sensitive to market movements. ELVN has a correlation of 0.02 to the broad based SPY ETF.

ELVN has a market cap of $3.88 billion. This is considered a Mid Cap stock.

In the last 3 years, ELVN traded as high as $62.32 and as low as $9.80.

The top ETF exchange traded funds that ELVN belongs to (by Net Assets): VTI, VXF, SCHA, XPH, VTWO.

ELVN has outperformed the market in the last year with a return of +182.6%, while the SPY ETF gained +18.3%. In the last 3 month period, ELVN beat the market returning +46.8%, while SPY returned +5.6%. However, in the most recent 2 weeks ELVN has underperformed the stock market by returning -10.2%, while SPY returned -0.9%.

ELVN support price is $54.95 and resistance is $57.52 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ELVN shares will trade within this expected range on the day.